Researchers at Carnegie Mellon University have developed a groundbreaking lens technology that enables a camera to focus on ...
As of Monday, December 29, Aligos Therapeutics, Inc.’s ALGS share price has dipped by 5.24%, which has investors questioning ...
Discover why Edgewise Therapeutics, Inc. is rated Buy amid strong trial data, unique HCM treatment, and major 2026 catalysts. Click for this EWTX update.
A new microchip-sized device could dramatically accelerate the future of quantum computing. It controls laser frequencies ...
This move represented a sharp increase in price on volume nearly 3x the average daily trading volume, indicating robust ...
Unidad de Gestión Clínica de Salud Mental, Instituto IBIMA, Hospital Regional Universitario, Málaga E-29010, Spain ...
Clinical Trials Arena on MSN
Leads Biolabs and DNTH initiate trial of LBL-047 in SLE
The study has a two-part, placebo-controlled, double-blind, randomised, dose-escalation (single ascending dose) design.
Reviva Pharmaceuticals Holdings Inc. may be headed back to the clinic for another phase III study of brilaroxazine in treating schizophrenia. With a successful series of early and mid-stage studies ...
“Photon Design's next-generation, EPIPPROP simulator, will offer the flexibility to split waveguides, simulating this process ...
An announcement from Shionogi & Co ( ($JP:4507) ) is now available. Shionogi has received Japanese regulatory approval to manufacture and market ...
Athira Pharma has joined an attempt to rescue an asset abandoned by Pfizer. The biotech has secured near-global rights to a phase 3 breast cancer prospect in a deal with Sermonix Pharmaceuticals.
Results showed CNS target engagement with reduction in GCase substrate glucosylsphingosine (GluSph) in cerebrospinal fluid (CSF), a prespecified ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback